Log In
Print
BCIQ
Print
Print this Print this
 

AVA-101

  Manage Alerts
Collapse Summary General Information
Company Avalanche Biotechnologies Inc.
DescriptionAdeno-associated virus (AAV) vector-based therapy that delivers soluble vascular endothelial growth factor (VEGF) receptor 1 (sFLT1; sVEGFR-1), a VEGF inhibitor
Molecular Target Vascular endothelial growth factor (VEGF)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today